Karin M. Otte;Paul Tempest;Richard W. Heidebrecht, JR.;David J. Witter;Thomas A. Miller;Phieng Siliphaivanh;Paul Harrington;Kevin J. Wilson;Solomon Kattar;Matthew G. Stanton
发明人:
Paul Harrington,Richard W. Heidebrecht, JR.,Solomon Kattar,Thomas A. Miller,Karin M. Otte,Phieng Siliphaivanh,Matthew G. Stanton,Paul Tempest,Kevin J. Wilson,David J. Witter
申请号：
US13751789
公开号：
US20130137690A1
申请日:
2013.01.28
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.
